--- title: "NervGen Pharma (NGEN) news: offering" url: "https://aibio.space/companies/nervgen-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NGEN offering news: NervGen reports C$86,789,698 cash after May 2026 public offering. NervGen Pharma Corp. (NASDAQ: NGEN), Canada." --- NGEN NervGen Pharma Corp. NASDAQ · Canada # NervGen Pharma (NGEN) news NGEN offering news Financings · 2026-08-13 ## [NervGen reports C$86,789,698 cash after May 2026 public offering](https://aibio.space/news/nervgen-reports-c-86-789-698-cash-after-may-2026-public-offering/) NervGen's cash rose to C$86,789,698 after a May 2026 offering of 24,000,000 units. Its warrant liability climbed to C$68,625,899, and a related party bought 800,000 of the units. ## Latest NervGen Pharma news 1. 2026-05-18 Listings [NervGen reports $16.6 million cash and investments after Nasdaq listing](https://aibio.space/news/nervgen-reports-16-6-million-cash-investments-after-nasdaq-listing/) NervGen's first-quarter net loss narrowed on a non-cash warrant gain, while its annual filing shows a 2025 net loss of CAD 44.1 million. The company says all its clinical plans remain subject to more funding. ## NervGen Pharma at a glance - **Ticker**: NGEN - **Listing**: NASDAQ - **Country**: Canada - **Cash, Dec 31, 2025**: C$22.1 million ### Related companies - [EASTGATE BIOTECH CORP](https://aibio.space/companies/eastgate-biotech/) OTC: ETBI - [Xenon Pharmaceuticals](https://aibio.space/companies/xenon-pharmaceuticals/) NASDAQ: XENE - [Nurexone Biologic](https://aibio.space/companies/nurexone-biologic/) TSXV: NRX - [Medexus Pharmaceuticals](https://aibio.space/companies/medexus-pharmaceuticals/) TSX: MDP - [Waverley Pharma](https://aibio.space/companies/waverley-pharma/) TSXV: WAVE - [Psyence Biomedical](https://aibio.space/companies/psyence-biomedical/) NASDAQ: PBM - [PharmAla Biotech Holdings](https://aibio.space/companies/pharmala-biotech/) CSE: MDMA - [Cannamerica Brands](https://aibio.space/companies/cannamerica-brands/) OTC: CNNXF ### Also on NASDAQ - [Axsome Therapeutics](https://aibio.space/companies/axsome-therapeutics/) AXSM - [NATURAL ALTERNATIVES INTERNATIONAL INC](https://aibio.space/companies/natural-alternatives-international/) NAII - [uniQure](https://aibio.space/companies/uniqure-n-v/) QURE - [Instil Bio](https://aibio.space/companies/instil-bio/) TIL - [Arvinas](https://aibio.space/companies/arvinas/) ARVN - [Natera](https://aibio.space/companies/natera/) NTRA ## NervGen Pharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [C$13.9 million](https://www.sec.gov/Archives/edgar/data/1751912/000110465926037357/) | [C$15.8 million](https://www.sec.gov/Archives/edgar/data/1751912/000110465926037357/) | | Net income (loss) | [-C$44.1 million](https://www.sec.gov/Archives/edgar/data/1751912/000110465926037357/) | [-C$24.3 million](https://www.sec.gov/Archives/edgar/data/1751912/000110465926037357/) | | Cash from operations | [-C$19.5 million](https://www.sec.gov/Archives/edgar/data/1751912/000110465926037357/) | [-C$16.8 million](https://www.sec.gov/Archives/edgar/data/1751912/000110465926037357/) | | Cash and equivalents | [C$22.1 million](https://www.sec.gov/Archives/edgar/data/1751912/000110465926037357/) | [C$17.3 million](https://www.sec.gov/Archives/edgar/data/1751912/000110465926037357/) | Latest balance sheet, Dec 31, 2025 (40-F): cash and equivalents C$22.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about NervGen Pharma Has NervGen Pharma raised money recently? Our latest story on this, dated Aug 13, 2026: "NervGen reports C$86,789,698 cash after May 2026 public offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nervgen-reports-c-86-789-698-cash-after-may-2026-public-offering/). What is the ticker symbol of NervGen Pharma? NervGen Pharma Corp. trades under the ticker NGEN on NASDAQ. Where is NervGen Pharma listed? NervGen Pharma Corp. is listed on NASDAQ. Our directory also records these other listings: GETTEX:9UA; LS:A2QP3D; LSX:A2QP3D. What is the SEC CIK of NervGen Pharma? The SEC Central Index Key (CIK) for NervGen Pharma Corp. is 1751912. Its filings are on SEC EDGAR. Which country or territory is NervGen Pharma listed under? Our directory records NervGen Pharma Corp. under Canada. What does NervGen Pharma do? Our directory classifies NervGen Pharma Corp. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of NervGen Pharma? The ISIN recorded for NervGen Pharma Corp. is CA64082X2032. Does aibio.space cover NervGen Pharma? aibio.space lists NervGen Pharma Corp. among 2,820 public biotech companies and publishes its news here as stories appear. What is the latest NervGen Pharma (NGEN) stock news? Our latest story on NervGen Pharma, dated Aug 13, 2026: "NervGen reports C$86,789,698 cash after May 2026 public offering". NervGen's cash rose to C$86,789,698 after a May 2026 offering of 24,000,000 units. Its warrant liability climbed to C$68,625,899, and a related party bought 800,000 of the units. [Source](https://aibio.space/news/nervgen-reports-c-86-789-698-cash-after-may-2026-public-offering/). How long will NervGen Pharma's cash last? From our story of Aug 13, 2026: The going concern note says management forecasts that existing working capital will be sufficient for 12 months from the date the statements were issued. [Source](https://aibio.space/news/nervgen-reports-c-86-789-698-cash-after-may-2026-public-offering/). How much cash does NervGen Pharma have? From our story of May 18, 2026: It had cash and investments of $16.6 million at March 31, 2026. [Source](https://aibio.space/news/nervgen-reports-16-6-million-cash-investments-after-nasdaq-listing/). Is NervGen Pharma at risk of delisting? Our latest listing story, dated May 18, 2026: "NervGen reports $16.6 million cash and investments after Nasdaq listing". NervGen's first-quarter net loss narrowed on a non-cash warrant gain, while its annual filing shows a 2025 net loss of CAD 44.1 million. The company says all its clinical plans remain subject to more funding. [Source](https://aibio.space/news/nervgen-reports-16-6-million-cash-investments-after-nasdaq-listing/). Is NervGen Pharma a smaller reporting company? SEC records list NervGen Pharma Corp.'s filer category as:
Emerging growth company. Where is NervGen Pharma headquartered? SEC records list its business address as 112-970 BURRARD STREET, VANCOUVER, V6Z 2R4. When does NervGen Pharma's fiscal year end? NervGen Pharma Corp.'s fiscal year ends on December 31, per SEC records. ## Investor discussion: NervGen Pharma Members talk about NervGen Pharma (NGEN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at NervGen Pharma, newest first. Each line links the filing it comes from. 1. 2026-08-13 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1751912/000110465926095467/tm2623069d1_ex99-1.htm) 2. 2026-07-02 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1751912/000110465926080432/tm2619503d3_ex99-1.htm) 3. 2026-05-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1751912/000110465926063212/tm2614980d1_ex99-1.htm) 4. 2026-05-15 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1751912/000110465926062618/tm2614733d1_ex99-1.htm) 5. 2026-03-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1751912/000110465926027740/tm268804d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NGEN on TradingView](https://www.tradingview.com/symbols/NASDAQ-NGEN/). ## SEC filings and registration - **SEC name**: Nervgen Pharma Corp. - **CIK**: 1751912 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NGEN (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 112-970 BURRARD STREET, VANCOUVER, V6Z 2R4 - **Phone**: 7787311711 ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1751912/000110465926111004/tm2626184d1_6k.htm) filed 2026-09-25 - [6-K](https://www.sec.gov/Archives/edgar/data/1751912/000110465926110225/tm2625558d1_6k.htm) filed 2026-09-24 - [6-K](https://www.sec.gov/Archives/edgar/data/1751912/000110465926095467/tm2623069d1_6k.htm) filed 2026-08-13 - [6-K](https://www.sec.gov/Archives/edgar/data/1751912/000110465926080432/tm2619503d3_6k.htm) filed 2026-07-02 - [6-K](https://www.sec.gov/Archives/edgar/data/1751912/000110465926069028/tm2616544d1_6k.htm) filed 2026-06-01 - [6-K](https://www.sec.gov/Archives/edgar/data/1751912/000110465926066307/tm2615621d1_6k.htm) filed 2026-05-26 - [6-K](https://www.sec.gov/Archives/edgar/data/1751912/000110465926065821/tm2615291d1_6k.htm) filed 2026-05-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1751912/000110465926063212/tm2614980d1_6k.htm) filed 2026-05-18 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001751912), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details NervGen Pharma Corp. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NGEN, recorded under Canada. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: NervGen Pharma Corp. - **Ticker**: NGEN - **Listing**: NASDAQ - **Country or territory**: Canada - **Business scope**: Pharmaceuticals: Major - **ISIN**: CA64082X2032 - **Other listed symbols**: GETTEX:9UA; LS:A2QP3D; LSX:A2QP3D - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NGEN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nervgen-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "NervGen Pharma (NGEN) news: offering", 2026-10-31, https://aibio.space/companies/nervgen-pharma/